Predictors of acute kidney injury associated with intravenous colistin treatment

International Journal of Antimicrobial Agents

Volumn 35, Issue 5, 2010, Pages 473-477

  Kwon, Jeong Ah ^a   Lee, Jung Eun ^a   Huh, Wooseong ^a   Peck, Kyong Ran ^a   Kim, Yoon Goo ^a   Kim, Dae Joong ^a   Oh, Ha Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Acute kidney injury; Colistin; Nephrotoxicity; Risk factors

Indexed keywords

CALCINEURIN INHIBITOR; COLISTIN; CREATININE; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; COLISTIN; CREATININE; CROSS INFECTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77949657395     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.002     Document Type: Article

References (25)

1. Waterer G.W., Wunderink R.G. Increasing threat of Gram-negative bacteria. Crit Care Med 2001, 29:N75-N81.
2. Wareham D.W., Bean D.C., Khanna P., Hennessy E.M., Krahe D., Ely A., et al. Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008, 27:607-612.
3. Falagas M.E., Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, 40:1333-1341.
4. Li J., Nation R.L., Milne R.W., Turnidge J.D., Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005, 25:11-25.
5. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
6. Falagas M.E., Fragoulis K.N., Kasiakou S.K., Sermaidis G.J., Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005, 26:504-507.
7. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., Falagas M.E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121.
8. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
9. Ricci Z., Cruz D., Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008, 73:538-546.
10. Ali T., Khan I., Simpson W., Prescott G., Townend J., Smith W., et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007, 18:1292-1298.
11. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl. 1):S1-S266.
12. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
13. Kallel H., Hergafi L., Bahloul M., Hakim A., Dammak H., Chelly H., et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007, 33:1162-1167.
14. Kim J., Lee K.H., Yoo S., Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 2009, 34:434-438.
15. Lanese D.M., Conger J.D. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993, 91:2144-2149.
16. Fogarty B.J., Parks R.W., Rowlands B.J., Diamond T. Renal dysfunction in obstructive jaundice. Br J Surg 1995, 82:877-884.
17. Betjes M.G., Bajema I. The pathology of jaundice-related renal insufficiency: cholemic nephrosis revisited. J Nephrol 2006, 19:229-233.
18. Desai T.K., Tsang T.K. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988, 85:47-50.
19. Oliveira J.F., Silva C.A., Barbieri C.D., Oliveira G.M., Zanetta D.M., Burdmann E.A. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother 2009, 53:2887-2891.
20. Nanji A.A., Stewart D.J., Mikhael N.Z. Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 1986, 17:274-276.
21. Humes H.D. Aminoglycoside nephrotoxicity. Kidney Int 1988, 33:900-911.
22. Sawaya B.P., Briggs J.P., Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995, 6:154-164.
23. Levin A.S., Barone A.A., Penco J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1011.
24. Falagas M.E., Kasiakou S.K., Kofteridis D.P., Roditakis G., Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006, 25:596-599.
25. Pintado V., San Miguel L.G., Grill F., Mejia B., Cobo J., Fortun J., et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 2008, 56:185-190.